Hi guys,
Inference for this is April 2010 - April 2011 EBITDA is running at $3.6M . As EBITDA is 43% of
sales revenue that translates to sales of $8,500,000. Profit on the last half was 19% of sales revenue
thus current nett profit on a monthly basis extrapolated to a year is $1.6M. With 81 million shares
on issue that approx earning per share on 2 cents. Closing price today of 17 cents gives a forward
PE of 8.5. Sales revenue year on year increased 40% last year and expect 25% to 40% sales revenue
increase this year. As this is NOT accounted as well as more aquistions to come expect upgrades on EBITDA and profit to continue to be released to the market. NPAT of $5M after 3 years at this rate is achievable.
- Forums
- ASX - By Stock
- BGL
- powering ahead
powering ahead
Featured News
Add BGL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.32 |
Change
-0.095(6.71%) |
Mkt cap ! $1.689B |
Open | High | Low | Value | Volume |
$1.36 | $1.37 | $1.30 | $11.69M | 8.813M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 716 | $1.32 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.33 | 30000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 716 | 1.320 |
3 | 45000 | 1.315 |
10 | 264599 | 1.310 |
7 | 80466 | 1.305 |
24 | 255649 | 1.300 |
Price($) | Vol. | No. |
---|---|---|
1.325 | 30000 | 1 |
1.330 | 58914 | 4 |
1.335 | 21617 | 1 |
1.340 | 23017 | 2 |
1.345 | 26617 | 2 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
BGL (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online